Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sihuan Pharmaceutical announces that its subsidiary, Huisheng Biopharmaceutical, has received NMPA approval for its innovative Insulin Degludec and Insulin Aspart Injection, Huiyoujia, for treating type 2 diabetes in adults in China. This marks the first domestic biosimilar to Novo Nordisk’s original drug, offering a simpler administration method and mimicking near-physiological insulin secretion. The launch is expected to drive significant growth for the Group’s diabetes drug pipeline amid China’s rising diabetes prevalence.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.